Computational modeling of serum-binding proteins and clearance in extrapolations across life stages and species for endocrine active compounds

Risk Analysis

Volumn 24, Issue 3, 2004, Pages 751-770

  Teeguarden, Justin G ^a   Barton, Hugh A ^b,c  

^a ENVIRON Health Sciences Institute   (United States)

^b U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^c U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

Author keywords

Bisphenol A; Endocrine disruption; Estradiol; Genistein; Octylphenol; PBPK model; Risk assessment; Serum protein binding; SHBG

Indexed keywords

BIOCHEMICAL ENGINEERING; GENES; MATHEMATICAL MODELS; PHENOLS; PROTEINS;

GENE TRANSCRIPTIONS; SERUM-BINDING PROTEINS;

RISK ASSESSMENT;

4,4' ISOPROPYLIDENEDIPHENOL; BINDING PROTEIN; ESTRADIOL; ESTROGEN RECEPTOR; GENISTEIN; HORMONE RECEPTOR AFFECTING AGENT;

ENDOCRINE SYSTEM; PROTEIN; RISK ASSESSMENT;

BINDING AFFINITY; BLOOD LEVEL; DRUG POTENCY; GENETIC TRANSCRIPTION; HORMONE ACTION; MOLECULAR MODEL; QUANTITATIVE ANALYSIS; RECEPTOR BINDING; REVIEW;

ADULT; ALPHA-FETOPROTEINS; ANIMALS; CARRIER PROTEINS; ENDOCRINE GLANDS; ESTRADIOL; FEMALE; GENISTEIN; HUMANS; KINETICS; MALE; MODELS, BIOLOGICAL; PHENOLS; PREGNANCY; RATS; RECEPTORS, ESTROGEN; SERUM ALBUMIN; SEX HORMONE-BINDING GLOBULIN;

EID: 3042748133     PISSN: 02724332     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0272-4332.2004.00473.x     Document Type: Review

References (79)

1. Safe, S. (1998). Hazard and risk assessment of chemical mixtures using the toxic equivalency factor approach. Environmental Health Perspectives, 106(suppl. 4), 1051-1058.
2. Barton, H. A., & Andersen, M. E. (1998a). Endocrine active compounds: From biology to dose response assessment. Critical Reviews in Toxicology, 28(4), 363-423.
3. Soto, A. M. et al. (1995). The E-SCREEN assay as a tool to identify estrogens: An update on estrogenic environmental pollutants. Environmental Health Perspectives, 103(suppl. 7), 113-122.
4. Klotz, D. et al. (1996). Identification of environmental chemicals with estrogenic activity using a combination of in vitro assays. Environmental Health Perspectives, 104(10), 1084-1089.
5. Jobling, S. et al. (1995). A variety of environmentally persistent chemicals, including some phthalate plasticizers, are weakly estrogenic. Environmental Health Perspectives, 103(6), 582-587.
6. Danzo, B. (1997). Environmental xenobiotics may disrupt normal endocrine function by interfering with the binding of physiological ligands to steroid receptors and binding proteins. Environmental Health Perspectives, 105(3), 294-301.
7. Milligan, S. et al. (1998). Relative potency of xenobiotic estrogens in an acute in vivo mammalian assay. Environmental Health Perspectives, 106(1), 23-26.
8. Shelby, M. D. et al. (1996). Assessing environmental chemicals for estrogenicity using a combination of in vitro and in vivo assays. Environmental Health Perspectives, 104(12), 1296-1300.
9. Stahl, S. et al. (1998). Phytoestrogens act as estrogen agonists in an estrogen-responsive pituitary cell line. Toxicology and Applied Pharmacology, 152(1), 41-48.
10. Blair, R. M. et al. (2000). The estrogen receptor relative binding affinities of 188 natural and xenochemicals: Structural diversity of ligands. Toxicological Sciences, 54(1), 138-153.
11. Bradbury, S. et al. (2000). A computationally based identification algorithm for estrogen receptor ligands: Part 1. Predicting hERalpha binding affinity. Toxicological Sciences, 58(2), 253-269.
12. Waller, C. L. et al. (1996). Ligand-based identification of environmental estrogens. Chemical Research in Toxicology, 9(8), 1240-1248.
13. Walker, C. et al. (1999). Species, interindividual, and tissue specificity in endocrine signaling. Environmental Health Perspectives, 107(suppl. 4), 619-624.
14. Nagel, S. et al. (1998). The effective free fraction of estradiol and xenoestrogens in human serum measured by whole cell uptake assays: Physiology of delivery modifies estrogenic activity. Proceedings of the Society for Experimental Biology and Medicine, 217(3), 300-309.
15. Nagel, S. C. et al. (1997). Relative binding affinity-serum modified access (RBA-SMA) assay predicts the relative in vivo bioactivity of the xenoestrogens bisphenol A and octylphenol. Environmental Health Perspectives, 105(1), 70-76.
16. Barton, H. A., & Andersen, M. E. (1998). A model for pharmacokinetics and physiological feedback among hormones of the testicular-pituitary axis in adult male rats: A framework for evaluating effects of endocrine active compounds. Toxicological Sciences, 45(2), 174-187.
17. Greenstein, B. D. (1992). Effects of rat α-fetoprotein administration on estradiol free fraction, the onset of puberty, and neural and uterine nuclear estrogen receptors. Endocrinology, 130, 3184-3190.
18. Schlosser, P. et al. (2000). Final Report: Preliminary PBPK Modeling of Genistein. Chemical Industry Institute of Toxicology.
19. Katzenellenbogen, J. A. et al. (1996). Tripartite steroid hormone receptor pharmacology: Interaction with multiple effector sites as a basis for the cell- and promoter-specific action of these hormones. Molecular Endocrinology, 10(2), 119-131.
20. Mendel, C. M. (1992). The free hormone hypothesis: Distinction from the free hormone transport hypothesis. Journal of Andrology, 13(2), 107-116.
21. Pardridge, W., & Mietus, L. (1979). Transport of steroid hormones through the rat blood-brain barrier. Primary role of albumin-bound hormone. Journal of Clinical Investigation, 64(1), 145-154.
22. Laufer, L. R. et al. (1983). The effect of membrane permeability and binding by human serum proteins on sex steroid influx into the uterus. Journal of Clinical Endocrinology and Metabolism, 56(6), 1282-1287.
23. Tait, J., & Tait, S. (1991). The effect of plasma protein binding on the metabolism of steroid hormones. Journal of Endocrinology, 131(3), 339-357.
24. Plowchalk, D. R., & Teeguarden, J. G. (2002). Development of a physiologically based pharmacokinetic model for estradiol in rats and humans: A biologically motivated quantitative framework for evaluating responses to estradiol and other endocrine-active compounds. Toxicological Sciences, 69(1), 60-78.
25. Shibata, A. et al. (1999). Laboratory assay reproducibility of serum estrogens in umbilical cord blood samples. Cancer Epidemiology, Biomarkers and Prevention, 8(2), 147-151.
26. Montano, M. M. et al. (1995). Free estradiol in serum and brain uptake of estradiol during fetal and neonatal sexual differentiation in female rats. Biology of Reproduction, 53, 1198-1207.
27. Hammond, G. L. et al. (1980). Estimation of the percentage of free steroid in undiluted serum by centrifugal ultrafiltration-dialysis. Journal of Biological Chemistry, 255(11), 5023-5026.
28. Dziegielewska, K. M. et al. (1981). Proteins in cerebrospinal fluid and plasma of fetal rats during development. Developmental Biology, 83(1), 193-200.
29. Lai, P. C. et al. (1976). Rat alpha-fetoprotein: Isolation, radioimmunoassay and fetal-maternal distribution during pregnancy. Journal of Reproduction and Fertility, 48(1), 1-8.
30. Dunn, J. F. et al. (1981). Transport of steroid hormones: Binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma. Journal of Clinical Endocrinology and Metabolism, 53(1), 58-68.
31. Dean, M. et al. (1980). Serum protein binding of drugs during and after pregnancy in humans. Clinical Pharmacology and Therapeutics, 28(2), 253-261.
32. Hill, M. D., & Abramson, F. P. (1988). The significance of plasma protein binding on the fetal/maternal distribution of drugs at steady-state. Clinical Pharmacokinetics, 14(3), 156-170.
33. Zava, D., & Duwe, G. (1997). Estrogenic and antiproliferative properties of genistein and other flavonoids in human breast cancer cells in vitro. Nutrition and Cancer, 27(1), 31-40.
34. Plowchalk, D. R., & Teeguarden, J. (2002). Development of a physiologically based pharmacokinetic model for estradiol in rats and humans: A biologically motivated quantitative framework for evaluating responses to estradiol and other endocrine-active compounds. Toxicological Sciences, 69(1), 60-78.
35. Kuiper, G. G. J. M. et al. (1997). Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β. Endocrinology, 138(2), 863-870.
36. Nikov, G. N. et al. (2000). Interactions of dietary estrogens with human estrogen receptors and the effect on estrogen receptor-estrogen response element complex formation. Environmental Health Perspectives, 108(9), 867-872.
37. Moll, G. W., Jr. et al. (1981). Estradiol-testosterone binding interactions and free plasma estradiol under physiological conditions. Journal of Clinical Endocrinology Metabolism, 52(5), 868-874.
38. Dunn, J. (1984). Computer simulation of steroid transport in human plasma. In D. Rodbard & G. Forti (Eds.), Computers in Endocrinology, Vol. 14 (pp. 277-285). New York: Raven Press.
39. Dechaud, H. et al. (1999). Xenoestrogen interaction with human sex hormone-binding globulin (hSHBG). Steroids, 64(5), 328-334.
40. Masseyeff, R. et al. (1975). Evolution of alpha-fetoprotein serum levels throughout life in humans and rats, and during pregnancy in the rat. Annals of the New York Academy of Sciences, 259, 17-28.
41. Payne, D. W., & Katzenellenbogen, J. A. (1979). Binding specificity of rat alpha-fetoprotein for a series of estrogen derivatives: Studies using equilibrium and nonequilibrium binding techniques. Endocrinology, 105(3), 745-753.
42. Aussel, C. et al. (1975). Rat alpha-fetoprotein: Isolation, characterization and estrogen-binding properties. Biochimie, 55(11), 1431-1437
43. Keel, B. A., & Abney, T. O. (1984). The kinetics of estrogen binding to rat alpha-fetoprotein. Experientia, 40(5), 503-505.
44. Nunez, E. et al. (1974). Comparative study on the binding of estrogens by human and rat serum proteins in development. Biochemical and Biophysical Research Communications, 57(1), 126-133.
45. Nishi, S. et al. (1991). Localization of the estrogen-binding site of alpha-fetoprotein in the chimeric human-rat proteins. Proceedings of the National Academy of Sciences USA, 88(8), 3102-3105.
46. Vladusic, E. A. et al. (2000). Expression and regulation of estrogen receptor beta in human breast tumors and cell lines. Oncology Reports, 7(1), 157-167.
47. Martin, P. et al. (1978). Phytoestrogen interaction with estrogen receptors in human breast cancer cells. Endocrinology, 103(5), 1860-1867.
48. Milligan, S. et al. (1998). Competitive binding of xenobiotic oestrogens to rat alpha-fetoprotein and to sex steroid binding proteins in human and rainbow trout (Oncorhynchus mykiss) plasma. General and Comparative Endocrinology, 112(1), 89-95.
49. Martin, M. et al. (1996). Interactions between phytoestrogens and human sex steroid binding protein. Life Sciences, 58(5), 429-436.
50. Hodgert Jury, H. et al. (2000). Interactions between human plasma sex hormone-binding globulin and xenobiotic ligands. Journal of Steroid Biochemistry and Molecular Biology, 75(2-3), 167-176.
51. Baker, M. et al. (1998). Flavonoids inhibit estrogen binding to rat alpha-fetoprotein. Proceedings of the Society for Experimental Biology and Medicine, 217(3), 317-321.
52. Kuiper, G. et al. (1998). Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology, 139(10), 4252-4263.
53. Matthews, J. B. et al. (2001). In vitro and in vivo interactions of bisphenol A and its metabolite, bisphenol A glucuronide, with estrogen receptors alpha and beta. Chemical Research in Toxicology, 14(2), 149-157.
54. Csanady, G. A. et al. (2002). Distribution and unspecific protein binding of the xenoestrogens bisphenol A and daidzein. Archives of Toxicology, 76(5-6), 299-305.
55. Waynford, H. B., & Flecknell, P. A. (1992). Experimental and Surgical Technique in the Rat. New York: Academic Press.
56. Stock, B. et al. (1980). Serum protein binding of drugs during and after pregnancy in rats. Journal of Pharmacology and Experimental Therapeutics, 212(2), 264-268.
57. Dunn, J. (1983). Transport of estrogens in human plasma. In G. Merriam & M. Lipsett (Eds.), Catechol Estrogens (pp. 167-176). New York: Raven Press.
58. Hamar, C., & Levy, G. (1980). Serum protein binding of drugs and bilirubin in newborn infants and their mothers. Clinical Pharmacology and Therapeutics, 28(1), 58-63.
59. Adlercreutz, H., & Luukkainen, T. (1970). Identification and determination of oestrogens in various biological materials in pregnancy. Annals of Clinical Research, 2(4), 365-380.
60. Reyes, F. I. et al. (1974). Studies on human sexual development. II. Fetal and maternal serum gonadotropin and sex steroid concentrations. Journal of Clinical Endocrinology and Metabolism, 38(4), 612-617.
61. Clark, J. H., & Peck, E. J. Jr. (1979). Female sex steroids. Receptors and function. In F. Gross et al. (Eds.), Monographs on Endocrinology (p. 245). Berlin: Springer-Verlag.
62. Bawaarshi-Nassar, R. et al. (1989). Nasal absorption and metabolism of prrogestrone and 17-beta-estradiol in the rat. Drug Metabolism and Disposition, 17, 248-254.
63. Upmeier, A. et al. (2000). Toxicokinetics of bisphenol A in female DA/Han rats after a single i.v. and oral administration. Archives of Toxicology, 74(8), 431-436.
64. Nagata, C. et al. (1997). Decreased serum estradiol concentration associated with high dietary intake of soy products in premenopausal Japanese women. Nutrition and Cancer, 29(3), 228-233.
65. Dunn, J. F. (1984). Computer simulation of steroid transport in human plasma. Serono Symp. Publ. Raven Press 14 (Computational Endocrinology), 277-285.
66. Dunn, J. F. (1983). Transport of estrogens in human plasma. In G. R. Merriam (Ed.), Catechol Estrogens (pp. 167-176). New York: Raven Press.
67. Calvo, M. et al. (1988). Fatty acids bound to alpha-fetoprotein and albumin during rat development. Biochimica et Biophysica Acta, 959(3), 238-246.
68. Savu, L. et al. (1981). Mouse alpha 1-fetoprotein and albumin. A comparison of their binding properties with estrogen and fatty acid, ligands. Journal of Biological Chemistry, 256(18), 9414-9418.
69. Diver, M. J. (1993). The effect of free fatty acids on the in-vitro binding of testosterone in human plasma. Journal of Endocrinology, 136(2), 327-330.
70. Key, T. et al. (1990). The relationship of free fatty acids with the binding of oestradiol to SHBG and to albumin in women. Journal of Steroid Biochemistry, 35(1), 35-38.
71. Takeuchi, T., & Tsutsumi, O. (2002). Serum bisphenol a concentrations showed gender differences, possibly linked to androgen levels. Biochemical and Biophysical Research Communications, 291(1), 76-78.
72. Rolan, P. E. (1994). Plasma protein binding displacement interactions-Why are they still regarded as clinically important? British Journal of Clinical Pharmacology, 37(2), 125-128.
73. Sansom, L. N., & Evans, A. M. (1995). What is the true clinical significance of plasma protein binding displacement interactions? Drug Safety, 12(4), 227-233.
74. Zubenko, G. S., & Sunderland, T. (2000). Geriatric psychopharmacology: Why does age matter? Harvard Review of Psychiatry, 7(6), 311-333.
75. Grandison, M. K., & Boudinot, F. D. (2000). Age-related changes in protein binding of drugs: Implications for therapy. Clinical Pharmacokinetics, 38(3), 271-290.
76. Ritschel, W. A. (Ed.). (1988). Gerontokinetics. Pharmacokinetics of Drugs in the Elderly. Telford Press, Inc.
77. Bendridi, N. et al. (2002). Intravenous injection of human sex steroid hormone-binding globulin in mouse decreases blood clearance rate and testicular accumulation of orally administered [2-125I]iodobisphenol A. Steroids, 67(7), 637-645.
78. Bruce, N. (1976). The distribution of blood flow to the reproductive organs of rats near term. Journal of Reproduction and Fertility, 46(2), 359-362.
79. ILSI. (1994). Physiological Parameter Values for PBPK Models. International Health Sciences Institute, Risk Sciences Institute.